214 related articles for article (PubMed ID: 29845253)
1. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
Ding XF; Zhou J; Chen G; Wu YL
Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
[TBL] [Abstract][Full Text] [Related]
2. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
[TBL] [Abstract][Full Text] [Related]
3. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
4. β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.
Dere R; Perkins AL; Bawa-Khalfe T; Jonasch D; Walker CL
J Am Soc Nephrol; 2015 Mar; 26(3):553-64. PubMed ID: 25313256
[TBL] [Abstract][Full Text] [Related]
5. Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells.
Chowdhury P; Perera D; Powell RT; Talley T; Tripathi DN; Park YS; Mancini MA; Davies P; Stephan C; Coarfa C; Dere R
Sci Rep; 2021 May; 11(1):10461. PubMed ID: 34002003
[TBL] [Abstract][Full Text] [Related]
6. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
7. Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).
Martin B; Chesnel F; Delcros JG; Jouan F; Couturier A; Dugay F; Le Goff X; Patard JJ; Fergelot P; Vigneau C; Rioux-Leclerq N; Arlot-Bonnemains Y
PLoS One; 2013; 8(6):e67071. PubMed ID: 23785518
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL.
Hasanov E; Chen G; Chowdhury P; Weldon J; Ding Z; Jonasch E; Sen S; Walker CL; Dere R
Oncogene; 2017 Jun; 36(24):3450-3463. PubMed ID: 28114281
[TBL] [Abstract][Full Text] [Related]
12. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
13. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
Shang D; Xu X; Wang D; Li Y; Liu Y
World J Urol; 2013 Dec; 31(6):1547-54. PubMed ID: 23588815
[TBL] [Abstract][Full Text] [Related]
15. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
17. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma.
Kang HM; Noh KH; Chang TK; Park D; Cho HS; Lim JH; Jung CR
Cell Death Dis; 2019 Mar; 10(4):279. PubMed ID: 30902965
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
20. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.
An J; Liu H; Magyar CE; Guo Y; Veena MS; Srivatsan ES; Huang J; Rettig MB
Cancer Res; 2013 Feb; 73(4):1374-85. PubMed ID: 23393199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
